Jump to main content
Jump to site search


Cryoablation-Activated Enhanced Nanodoxorubicin Release for the Therapy of Chemoresistant Mammary Cancer Stem-like Cells

Abstract

Chemoresistance is a common property of tumor-initiating cancer stem-like cells. Overcoming chemoresistance, particularly in cancer stem-like cells, can markedly enhance the efficacy of cancer therapy and prevent cancer recurrence and metastasis. This study demonstrates that temperature-negative expansion nanodrugs could achieve the controllable and enhanced release of anticancer drugs when combined with cryoablation and effectively overcome chemoresistance in mammary cancer stem-like cells. The enhanced destruction of both cancer stem-like cells and cancer cells resulted in the improved inhibition of second-generation tumor formation in vitro. Furthermore, nanodrug-mediated cryosurgery did not produce systemic toxicity and had superior antitumor effects in a xenograft tumor model. Collectively, this study demonstrates the strong potential of thermally sensitive nanodrug-mediated cryoablation for overcoming chemoresistance in cancer stem-like cells and markedly improving overall treatment efficacy against breast cancer.

Back to tab navigation

Supplementary files

Article information


Submitted
05 Sep 2019
Accepted
02 Jan 2020
First published
02 Jan 2020

J. Mater. Chem. B, 2020, Accepted Manuscript
Article type
Paper

Cryoablation-Activated Enhanced Nanodoxorubicin Release for the Therapy of Chemoresistant Mammary Cancer Stem-like Cells

Y. Hou, X. Sun, S. Yao, W. Rao and X. He, J. Mater. Chem. B, 2020, Accepted Manuscript , DOI: 10.1039/C9TB01922G

Social activity

Search articles by author

Spotlight

Advertisements